Home
Company
Company

Press Kit
Contact

Principals

Robert A. Casper, Ph.D
David L. Gardner, Ph.D

Gastrointestinal
Devices

InteliSite
Articles
Clinical Trials/Studies

Respiratory Devices

Services
Articles

Links

Phone (919) 781-6315

email
devices@mindspring.com

Principals

David L. Gardner, Ph.D.
7 Bloomsbury Court
Chapel Hill, NC 27514
Office Phone: 919-781-6315
Home Phone: 919-490-6966
December 6, 2000


PROFESSIONAL SUMMARY:

Proven record of achieving goals in managing multi-disciplinary research and development programs within time and cost constraints. Broad experience in development of novel drug/device delivery systems for the pharmaceutical market. Distinguished record of publications and patents.

WORK HISTORY:

Partner, Innovative Devices, LLC, 6008-101 Triangle Drive, Raleigh, NC, 1/95 to present

Innovative Devices, LLC (IDL) is a North Carolina limited liability company founded in January, 1995 to provide research, development and manufacturing of novel medical devices for the more effective administration of existing therapeutic drugs or drugs under development. Specifically, IDL maintains a focus on inhalation devices for use in administering drugs to the respiratory tract and a device (InteliSite® capsule) which can be targeted to specific sites in the gastrointestinal tract for studying the absorption and/or bioavailability of drugs. IDL has filed patent applications on two inhalation devices and owns issued patents covering the InteliSite® capsule.

Director, Allen & Hanbury's (A&H) Pharmaceutical Development, Pharmaceutical Development, Glaxo Inc., Research Triangle Park, NC, 8/92 to 12/94

Responsibilities included the following:
  • Served as the primary interface between the A&H SBU and GRI Pharmaceutical Development groups as regards R&D projects.
  • Managed, led and coordinated external R&D contracts related to A&H line extensions or novel respiratory delivery systems.
  • Identified, evaluated and implemented new technologies that would play a strategic position in future A&H marketed products.
  • Worked closely with A&H Marketing, Medical Affairs, Corporate Strategic Development and Licensing in identifying future respiratory product development needs.
  • Participated in the Exploratory Devices Committee to strategically position novel respiratory delivery systems for A&H marketing needs.
  • Identified consultants for R&D projects. These consultants served the primary role of critiquing the program as well as providing valuable technical input into the R&D effort.
  • Identified potential outside organizations which possessed the necessary capabilities in aerosol research or contract manufacturing to support A&H product development efforts.
  • Updated and maintained an accurate profile of on-going research projects/contracts, via a computer software program.
  • Worked closely with the Clinical Respiratory Group at Glaxo Inc in coordinating and planning of clinical trials to support new device developments.
 Director, Pharmaceutics Extramural R&D, Pharmaceutical Development, Glaxo Inc., Research Triangle Park, NC, 3/90 to 7/92
  • Responsible for monitoring, evaluating and coordinating the research and development efforts of external contracts and grants.
  • Worked closely with the Clinical Respiratory Group within A&H Medical Development in coordinating and planning of clinical trials to support new device developments.
  • Responsible for working closely with Marketing and Licensing personnel in identifying new product development needs.
  • Responsible for working closely with the Pharmaceutics staff in identifying and implementing external R&D contracts.
  • Responsible for identifying new developing technologies and to relate that technology to Glaxo Inc.'s therapeutic areas (existing drugs or new chemical entities).
Head, Extramural Pharmaceutical R&D, Pharmaceutical Development, Glaxo Inc., Research Triangle Park, NC, 5/87 to 2/90
  • Responsible for project management within Pharmaceutical Development of external new product development projects; primary individual responsible for getting these products developed and marketed.
  • Responsible for suggesting new products and new product ideas in the realm of new dosage forms, novel delivery systems and new packaging technologies.
Senior Research Scientist, Battelle Columbus Laboratories, Columbus, Ohio, 1985 to 5/87
  • Coordinated and managed simultaneously five-six multi-disciplinary research contracts for industrial clients, ranging each in dollar value from $50,000 - $100,000.
  • Directed the continued development and marketing of Battelle microencapsulation capabilities as related to drug delivery systems to industrial and government clients.
  • Managed and supervised 6-8 research scientists and technicians.
Principal Research Scientist, Batelle Columbus Laboratories, Columbus, Ohio, 1981 to 1985
  • Coordinated and managed multi-disciplinary contract research programs related to controlled release of large molecular weight proteins, e.g., bovine growth hormone.
  • Managed and supervised 5-6 research scientists and technicians.
  • Phase I clinical studies were started in chronic uremic patients - based upon an ingestible microcapsule system developed earlier.
 Principal Physiologist - Batelle Columbus Laboratories, Columbus, Ohio, 1973 to 1981
  • Developed ingestible absorbent microcapsule systems for control of metabolites in chronic uremic patients.
  • Investigated and developed a sustained release (8-12 hours) oral delivery system for asthma control.
 Senior Physiologist - Batelle Columbus Laboratories, Columbus, Ohio, 1971 to 1973
  • Evaluated an orally ingested multi-enzyme microcapsule system in dogs for the control of hyperuricemia. Developed an osmotically active dye microcapsule system for use in a diagnostic test.
 Research Biochemist - Batelle Columbus Laboratories, Columbus, Ohio, 1969 to 1971
  • Investigated a novel reproductive delivery system in monkeys and baboons; based upon transcervical migration of microspheres/microcapsules.
  • Investigated an orally ingested detoxicant microcapsule system in dogs for removal of uremic waste products.
 Research Assistant, Department of Cardiovascular Research, Akron City Hospital, Akron, Ohio, 1967 to 1969
  • Developed synthetic vascular prostheses for small vessel replacement in calves at the Cleveland Clinic.
  • Investigated attachment and slow release of heparin from synthetic vascular prostheses.
 Research Chemist, Goodyear Tire and Rubber Company, Akron, Ohio, 1965 to 1967
  • Fabricated and evaluated artificial hearts for total heart replacement in calves at the Cleveland Clinic.
 Biology Instructor, Kent State University, Kent, Ohio, 1962 to 1967
  • Responsible for teaching Zoology and General Biology to undergraduate students at KSU extension centers.

EDUCATION:

1969, Ph.D., Biological Sciences/Physiology, Kent State University, Kent, Ohio
Dissertation: Stability of 35S-heparin attached to a modified polyurethane vascular prosthetic.

1963, M.A., Biology, Kent State University, Kent, Ohio
Thesis: The effect of Compazine’ on the metabolism of the gerbil.

1960, B.A., Biology, Kent State University, Kent, Ohio

HONORS:

Received Teaching and Research Assistantships throughout graduate studies. Invited lecturer to Center for Professional Development on Microencapsulation.

ACTIVITIES AND INTERESTS:

Member of the Controlled Release Society of Bioactive Materials, AAPS, and ISAM. Past member of AAAS, LES Society, Aerosol Science and Technology, and American Society of Artificial Internal Organs. Interests include all forms of athletics. Hobbies include the stock market, Indian relics, coins, and oil painting.

BOOK CONTRIBUTIONS:

1. D. L. Gardner and B. A. Metz, "Controlled Release of Anti-Fertility Agents", Bioactive Polymeric Systems, Eds. C. G. Gebelin and C. E. Carraher, Plenum Press, New York, pp. 93-119 (1985).

2. D. L. Gardner and C. R. Hassler, "Emerging Routes of Delivery for Fertility-Control Agents", Future Aspects in Contraception, Part 2, Female Contraception, Eds. B. Runnebaum, T. Rabe, and L. Kiesel, MTP Press, Ltd., England, pp. 83-93 (1985).

3. D. L. Gardner, D. J. Fink, and C. R. Hassler, "Potential Delivery of Contraceptive Agents to the Female Reproductive Tract", Controlled Release of Pesticides and Pharmaceuticals, Ed. D. H. Lewis, Plenum Press, New York, pp. 99-109 (1981).

4. D. L. Gardner and D. J. Fink, "Biodegradable Microcapsules and Microparticles for Contraception", Progress in Contraception Delivery Systems, Eds. E. S. E. Hafez and W. A. A. Van Os, MTP Press, Ltd., England, pp. 47-62 (1980).

5. D. L. Gardner and D. C. Emmerling, "Stabilized Urease Microencapsulated", Ed. T. M. S. Chang, Biomedical Applications of Immobilized Enzymes and Proteins, Vol. 1, Plenum Press, New York, pp. 163-170 (1977).

6. D. L. Gardner, D. J. Fink, A. J. Patanus, and C.R. Hassler, "Steroid Release in Cellulose Acetate Butyrate Microcapsules", Eds. D. L. Paul and F. W. Harris, Amer. Chem. Soc. Symp. Series (#33), Washington, D. C., pp. 171-181 (1976).

U.S. PATENTS

1. Sharp, W. V., Gardner, D. L., and Andresen, G. J., "Bioelectric Polyurethane and Use of Same in Internal Prostheses", U.S. Patent 3,512,183, issued May 19, 1970.

2. Gardner, D. L., "Dual Microcapsules and Process for Their Preparation", U.S. Patent 4,532,123, issued July 30, 1985.

3. Gardner, D. L., "Process of Preparing Microcapsules", U.S. Patent 4,637,905 issued January 20, 1987.

4. Benton, B. F. and Gardner, D. L., "Controlled Release Liquid Dosage Formulation", U.S. Patent 4,876,094, issued October 24, 1989.

5. Casper, R. A., Leith, F. A., and Gardner, D. L., "Dry Powder Medicament Inhalator Having An Inhalation-Activated Flow Diverting Means for Triggering Delivery Of Medicament", Notice of allowance, May, 1997.

6. Casper, R.A., Leith, F.A., and Gardner, D. L., "Dry Powder Medicament Inhalator Having An Inhalation-Activated Flow Diverting Means For triggering
Delivery Of Medicament", U.S. Patent # 5,823,183, issued October 20, 1998.

7. Casper, R.A., Leith, F.A., and Gardner, D. L., "Device for Use with Metered Dose Inhalers (MDIs)", U.S. Patent # 5,826,571, issued October 27, 1998.

8. Casper, R.A., Leith, F.A., and Gardner, D. L., "Device for Use with Metered Dose Inhalers (MDIs)", WO 99/06091, issued February 11, 1999.

9. Casper, R.A., Leith, F.A., and Gardner, D. L., "Dry Powder Medicament Inhalator Having An Inhalation-Activated Flow Diverting Means For triggering Delivery Of Medicament", U.S. Patent # 5,988,163, issued November 23, 1999.


PUBLICATIONS, PRESENTATIONS and ABSTRACTS

1. Gardner, D., Casper, R., Leith, F., and Wilding, I., "Non-invasive Methodology for Assessing Drug Regional Absorption from the Gastrointestinal Tract", Pharmaceutical Technology Europe (1997).

2. Gardner, D., Casper, R., Leith, F, and Wilding, I., "Non-Invasive Methodology for Assessing Drug Regional Absorption from the Gastrointestinal Tract", Pharmaceutical Technology Europe (June,1997).

3. Bosch, W. H., Bondanza, D. M., Casper, R. A., Gardner, D. L, and Leith, F. A., "Nebulization and Cascade Impactor Studies with a Beclomethasone Dipropionate NanoCrystal” Suspension", Abstract, Aerosol Therapy with Small Volume Nebulizers: Laboratory to Bedside, Tours, France, Sept. 4, 5 (1996).

4. Gardner, D. L., "Status of Medical Aerosol/Particulate Delivery Systems", 1996 Conference on Pharmaceutical Science and Technology, Chicago, IL August 6-8 (1996).

5. Gardner, D. L., "Remote Controlled Oral Delivery Systems-How Can Gamma Scintigraphy Help?", Conference on Pharmaceutical Science and Technology, Chicago, IL, August 23-25 (1995).

6. Gardner, D. L., "Aerosol Delivery and Distribution Profiles", Conference on Pharmaceutical Science and Technology, Chicago, IL August 23-25 (1995).

7. Gardner, D. L., "Licensing as a Team Sport (How to coordinate departments within your company to evaluate and negotiate an opportunity)", Panel Member, Licensing Executive Society Annual Meeting (1993).

8. Carter, D. H., Luttinger, M. and Gardner, D. L., "Controlled Release Parenteral Systems for Veterinary Applications", J. Controlled Release, 8, 15-22 (1988).

9. Gardner, D. L., Kjellstrand, C. M., Hassler, C. R., Fink, D. J. and Emmerling, D. C., "An Orally Administered Microcapsule System for Treating Chronic Renal failure Patients", Appl. Biochem. Biotech., 10, 27040 (1984).

10. Gardner, D. L. and Hassler, C. R., "Emerging Routes of Delivery for Fertility Control Agents", Symp. Future Aspects in Contraception, September 5-8, Heidelberg, West Germany (1984).

11. Gardner, D. L., "Contraceptive Delivery Systems", RxPO Conference, Controlled Release Drug Systems I & II, June 19-21, New York, NY (1984).

12. Gardner, D. L., Hassler, C. R., and Emmerling, D. C., "Sorbents for Therapeutic Applications", 36th ACEMB, Columbus, OH, September 12-14, p. 47 (1983).

13. Gardner, D. L., Hoffsis, G. F., Benton, B. F. and Metz, B. A., "Development of a Magnesium Dosage Form for Treatment of Hypomagnesemia", 10th Int. Symp. on Controlled Release of Bioactive Materials, San Francisco, CA, July 24 -27, pp. 57-66 (1983).

14. Gardner, D. L., "Novel Delivery Systems by Microencapsulation", Conference on Advances in Polymer Technologies: Implications in Industry, Batelle Technical Inputs to Planning, Columbus, OH, April 26, 27 (1983).

15. Gardner, D. L., Kjellstrand, C. M., Hassler, C. R., Fink, D. J. and Emmerling, D. C., "An Orally Administered Microcapsule System for Treating Chronic Renal Failure Patients", 5th Int. Symp. On Microencapsulation Including Artificial Cells, Montreal, Canada, May 2, 3 (1983).

16. Benton, B. F. and Gardner, D. L., "Microcapsules - Innovative, Versatile Product Delivery", Battelle Technical Inputs to Planning, Report #33, pp. 1-36 (1983).

17. Gardner, D. L., "Ingestible Microencapsulated Urease-Zirconium Phosphate for Urea Removal", Gordon Research Conference-Drug Carriers in Biology and Medicine, Plymouth, NH, July 12 -16 (1982).

18. Gardner, D. L., "Controlled Release of Pharmaceuticals", Symp. On Biomedical Applications of Polymers, Central and Great Lakes ACS Region, May 20-22 (1981).

19. Kjellstrand, C., Gorges, H., Pru, C., Gardner, D. L., and Fink, D.J., "Clinical Use of a Microencapsulated Enzyme System for Chronic Uremia", 6th Enz. Eng. Conf., Kashikojima, Japan, Sept. 20-25 (1981).

20. Gardner, D .L., "Biomedical Applications of Microcapsules", Conference on Advances in Polymer Technologies: Implications for Industry, Battelle Technical Inputs to Planning, Columbus, OH, May 20-21 (1981).

21. Kjellstrand, C., Borges, H., Pru, C., Gardner, D. L., and Fink, D. J., "Urease-Zirconium Phosphate Microcapsules (UZP) Effectively Decrease Nitrogen Accumulation in CRF Patients", 8th Int. Congress. Nephro., Atehsn, Greece, June 7-12 (1981).

22. Kjellstrand, C., Borges, H., Pru, C., Gardner, D. L., and Fink, D. J., "Urease-Zircomium Phosphate Microcapsules (UZP) Effectively Decrease Nitrogen Accumulation in CRF Patients", Amer. Soc. Artif. Int. Organs, 27, 24-30 (1981).

23. Gardner, D. L., Fink, D. J., and Benton, B. F., "Ethynyl Estradiol Release from Microcapsules and Prills", ACS Symposium on Advances in Polymeric Controlled Release Formulations, Houston, TX, March 23-27 (1980).

24. Gardner, D. L., Fink, D. J., and Hassler, C. R., "Potential Delivery of Contraceptive Agents to the Female Reproductive Tract", 7th Int. Symp. On Controlled Release of Bioactive Materials, Ft. Lauderdale, FL, July 27-30, pp. 77-80 (1980).

25. Gardner, D. L., "Application of Battelle Microencapsulation Process", Microencapsulation Workshop, Des Plains, IL, June 23-25 (1980).

26. Gardner, D. L., Fink, D. J., and Benton, B. F., "Development of Dosage Forms (Microencapsules) for Steroid Release", 4th Int. Symp. on Microencapsulation, Miami Beach, FL, March 26-30 (1979).

27. Benton, B. F. and Gardner, D. L., "Microencapsulation: A Dynamic Product Delivery System", Battelle Technical Inputs to Planning, Report No. 6, pp. 1-28 (1978).

28. Hughes, K. E., Gardner, D. L., Mosberg, A. T., Case, K. C., Browning, J. D., and Patanus, A. J., "Silicone Rubber as the Load Element of a Passive Artificial Muscle", 4th Annual Meeting. Soc. Biomater., San Antonio, TX (1978).

29. Hughes, K. E., Gardner, D. L., and Pinson, R. C., "A Passive Artificial Muscle System", 51st Annual Meeting, Assoc. Clin. Scient., Columbus, OH, April 22-24 (1977).

30. Gardner, D. L., Emmerling, D. C., Hughes, K. E., and Hassler, C.R., "Development of an Uremic Animal Model for Evaluating Ingestible Absorbents", 51st Ann. Mtg. Assoc. Clin. Scient., Columbus, OH, April 22-24 (1977).

31. Gardner, D. L., "Current Artificial Kidney Developments", Central Ohio Dialysis Association, Columbus, OH, May 10 (1977).

32. Hughes, K. E., Gardner, D. L., Mills, E. J., Hassler, C. R., and Pinson, R. C., "Materials for an Implantable Muscle", 3rd Ann. Meeting. Soc. Biomater, New Orleans, LA (1977).

33. Mills, E. J., Gardner, D. L., Hughes, K. E., and Pinson, R. C. "Load Measurements on Artificial Muscle Systems", Proceed. 29th Ann. Conf. Eng. Med. and Biol., p. 247 (1976).

34. Gardner, D. L., Fink, D. J., Patanus, A. J., and Hassler, C. R., "Steroid Release from Cellulose Acetate Butyrate Microcapsules", 171st Mtg. Amer. Chem. Soc., New York, NY, April 7-9 (1976).

35. Gardner, D.L., Patanus, A. J., and Fink, D. J., "Steroid Release from Microcapsules", NICHD Drug Delivery System Workshop, Bethesda, MD, pp. 265278 (1976).

36. Kim, B. C., Choi, P. S. K., Baytos, W. C., and Gardner, D. L., "Removal of Uremic Waste Products from Gastrointestinal Tract Using Microencapsulated Sorbents", 3rd Int. Symp. Microencap., Tokyo, Japan, Sept. 21-22 (1976).

37. Gardner, D. L., Emmerling, D. C., Wiiliamson, K. D., Baytos, W. C. and Hassler, C. R., "Encapsulated Absorbents for Removal of Nitrogenous Metabolites via Oral Ingestion", Kid. Int. 7: S-393-398 (1975).

38. Gardner, D. L., "Current Developments in the Treatment of Chronic Uremia-Artificial Kidneys", Central Ohio Dialysis Association, Columbus, OH, November 1718 (1975).

39. Gardner, D. L., "Intrauterine and Intestinal Microcapsules", Microencapsulated Workshop, Somerville, NJ, February 12-14 (1974).

40. Gardner, D. L., "Oral Nondialytic Approaches in Chronic Uremia", First Annual Interdisciplinary Conference on Biomedical Research Problems in a Changing World, Washington, D.C., February 5-7 (1974).

41. Gardner, D. L., Panelist on Working Luncheon entitled "Sorbents", Amer. Soc. Artif. Int. Organs, 20th Annual Meeting, Chicago, IL, April 3-5 (1974).

42. Gardner, D.L., Hassler, C.R., Baytos, W. B., Williamson, K. D., and Emmerling, D. C., "Intrauterine Microcapsules as a Drug Delivery Vehicle", Drug Therapy and Novel Delivery Systems Challenge and Responses Symposium", Seattle, WA, April 29-May 1 (1974).

43. Gardner, D. L., Hassler, C. R., Kim, B. C., Emmerling, D. C., Williamson, K. D. and Hughes, K. E., "Feasibility of Microencapsulated Detoxicants for Removal of Nitrogenous Metabolites via Ingestion and Characterization of Uremic Dog Gut Fluid", 7th Annual Contractors' Conference, Artificial Kidney-Chronic Uremia Program, Washington, D.C., January 28-30 (1974).

44. Sullivan, M. F., Gardner, D. L. and Kalkwarf, D. R., "The Pharmacologic Attack on Heroin Addiction", Research Outlook, 6 (1): 24-28 (1974).

45. Hassler, C. R., Gardner, D. L., Emmerling, D. C. and Hughes, K. E., "Chronically Implanted Percutaneous Triple Lumen Catheters for Characterization of Gut Perfusion Parameters in Azotemic and Normal Dogs", Amer. Soc. Artif. Int. Organs, 19, p. 27 (1973).

46. Gardner, D. L., Emmerling, D. C., Hassler, C. R., Williamson, K. D. and Hughes, K. E., "Net Water Movement and Flux Rates of Nitrogenous Metabolites in Azotemic and Control Dogs", Amer. Soc. Artif. Int. Organs, 19 , p. 23 (1973).

47. Gardner, D. L., Emmerling, D. C., Williamson, K. D., Hassler, C. R. and Baytos, W. C., "Combination Microcapsule for Controlling Chronic Uremia Urea Levels", Ann. Conf. Eng. Med and Biol., 26, p. 29.2 (1973).

48. Gardner, D. L., Hassler, C. R., Kim, B. C., Emmerling, D. C., Williamson, K. D., and Hughes, K. E., "Feasibility of Microencapsulated Detoxicants for Removal of Nitorgenous Metabolites via Ingestion and Characterization of Uremic Dog Gut Fluid", 6th Annual Contractors' Conference, Artificial Kidney Program, Washington, D.C., February 12-14 (1973).

49. Gardner, D. L., "Drug Delivery to Local Sites of Action via Microcapsules", 120th Metting of the Amer. Pharm. Assoc., Boston, MA, July 21-27 (1973).

50. Gardner, D. L., Hassler, C. R., Kim, B. C., and Emmerling, D. C., "Feasbility of Microencapsulated Detoxicants for Removal of Nitrogenous Metabolites via Ingestion", 5th Annual Contractors' Conference, Artificial Kidney Program, Washington, D.C., January 24-25 (1972).

51. Gardner, D. L., Emmerling, D. C., Hassler, C. R., and Kim, B. C., "Characterization of Nitrogenous Metabolites in Intestinal Fluid of Stabilized Uremic Dogs", Amer. Soc. Artif. Int. Organs, 18, p. 12 (1972).

52. Gardner, D. L., "Intrauterine Microcapsules", Microencapsulation Workshop, Woodbridge, NJ, September 26-28 (1972).

53. Gardner, D. L., "Removal of Nitrogenous Metabolites in Uremic Dog Intestinal Fluid via Microencapsulated Detoxicants", Amer. Soc. For Metals Symposium on Artificial Kidney and Gas Exchange Devices, Detroit, MI, May 12-14 (1971).

54. Gardner, D. L., Falb, R. D., and Kim, B. C., "Feasibility of Microencapsulated Detoxicants for Removal of Nitrogenous Metabolites via Ingestion", 4th Annual Contractors' Conference, Artificial Kidney Program, Washington, D.C., January 20-22 (1971).

55. Gardner, D. L., and Emmerling, D. C., "Microencapsulated Stabilized Urease", 162nd Amer. Chem. Soc. Mtg., Washington, D.C., (1971).

56. Gardner, D. L., Falb, R. D., Kim, B. C., and Emmerling, D. C., "Possible Uremic Detoxification via Oral-Ingested Microcapsules", Amer. Soc. Artif. Int. Organs, 17:239-245, (1971).

57. Gardner, D. L., Falb, R. D., and Kim, B. C., Feasibility of Microencapsulated Detoxicants for Removal of Metabolites via Ingestion", 3rd Annual Contractors' Conference, Artificial Kidney Program, Washington, D.C., January 14-16 (1970).

58. Gardner, D. L., Sharp, W. V., Ewing, K. L., and Finelli, R. F., "Stability of Herarin35S Attached to a Modified Polyurethane Vascular Prosthetic", Amer. Soc. Artif. Int. Organs, 15: 7-14, (1969).

59. Sharp, W. V., Gardner, D. L., Andresen, G. J., and Wright, J., "Electrolour: A New Vascular Interface", Amer. Soc. Artif. Int. Organs, 14: 73-77, (1968).

60. Gardner, D. L. and Sharp, W. V., "Electrolour: A New Vascular Interface", Cleveland Surgical Society, Cleveland, OH, April 25 (1967).

61. Pierson, R. M., Mathis, M. W., Wright, J., Gardner, D. L. and Finelli, A. F., Artificial Organs Based on Rubber", Int. Rubber Conference, England, Proceed. of the Int. Rubber Conf: 555-575 (1967).

62. Gardner, D. L. and Sharp, W. V., "Bioelectric Polyurethane Prosthesis," Cleveland Surgical Society, Cleveland, OH, May 10 (1966).

63. Sharp, W. V., Gardner, D. L., and Andresen, G. J., "A Bioelectric Polyurethane Elastomer for Intravascular Replacement", Amer. Soc. Artif. Int. Organs, 12: 179183, (1966).

64. Pierson, R. M., Finelli, A. F., Mathis, M. W., Martin, R. C., Gardner, D. L. and Camp, G. B., "The Portable Artificial Heart: Design Criteria and Prototype Evaluation", Chemical Engineering Progress Symposium, 62 (66): 1-10 (1966).

65. Gardner, D. L., "Goodyear's Artificial Heart Design", Amer. Soc. Artif. Int. Organs, 11:298 (1965).

66. Sharp, W. V., Gardner, D. L., and Andresen, G. J., "Adaptation of Elastic Materials for Small Vessel Replacement", Amer. Soc. Artif. Int. Organs, 11: 336-340 (1965).

67. Wilber, C. G., and Gardner, D. L., "The Effect of Compazine on the Metabolism of the Gerbil", ASTIA (DA-49-193-MD-2216): 1-60 (1963).

68. Wilber, C. G. and Gardner, D. L., "The Stimulating Effect of Hexamethonium Bromide on Physical Performance", ASTIA (DA-49-193-MD-2216): 1-11 (1963).

69. Gardner, D. L., and Wilber, C. G., "The Effect of Compazine on the Metabolism of the Gerbil", Ohio Academy of Science, 72nd Annual Meeting (1963).

70. Wilber, C. G. and Gardner, D. L., "Time Relations in the Electrocardiogram of the Gerbil", Ohio Academy of Science, 71st Annual Meeting (1962).